| Name | Title | Contact Details |
|---|
The Asahi Kasei Group contributes to life and living for people around the world. Since its foundation in 1922 with ammonia and cellulose fiber business, Asahi Kasei has consistently grown through the proactive transformation of its business portfolio to meet the evolving needs of every age. With more than 48,000 employees around the world, the company contributes to sustainable society by providing solutions to the worlds challenges through its three business sectors of Material, Homes, and Health Care.
Citizens Bank & Trust Company of Campbellsville, KY is a banking company based out of 201 E MAIN ST, Campbellsville, Kentucky, United States.
Creative Bus Sales is now Model 1 Commercial Vehicles. Nothing about passion or our leadership has changed, and our brand represents the creativity, expertise, and vision we put to work for customers across the U.S. As the largest bus and commercial transit dealership in the U.S., Model 1 is at the forefront of solving commercial and community transportation issues with visionary thinking – including not just vehicles but also distribution, parts, service, F&I, and more. Strong partnerships with more than 20 top manufacturers, the largest in-stock vehicle inventory in the country, and a nationwide team of experts, means theres no problem too big or too unique to solve together. Model 1 is the blueprint for creative commercial vehicle solutions. See why at model1.com.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.